B. Braun launched an app yesterday for its Easypump ST/LT elastomeric infusion pump to help patients and clinicians use the system more safely and efficiently for home infusion therapy. The Easypump app features graphics and videos that explain the infusion therapy process, B. Braun said, and provides nurses with tools to teach patients how to […]
Pharmaceuticals
SteadyMed studies accuracy and precision of PatchPump infusion system for Trevyent
SteadyMed (NSDQ:STDY) said yesterday that it finished a clinical study for its lead drug candidate, Trevyent. The pulmonary arterial hypertension treatment is a combination of treprostinil and the PatchPump prefilled, disposable infusion system. The San Ramon, Calif.-based company said it is on track to submit a New Drug Application for Trevyent in the 2nd quarter […]
Liposomal drug delivery system could improve solid tumor treatment
The oxygen-poor regions of solid tumors usually help make them resistant to chemotherapy and other forms of treatment. But researchers at Oregon State University have devised away to take advantage of those hypoxic areas and improve solid tumor treatment with a targeted, liposomal drug delivery system. The team used the cancer drug, vinblastine, which is […]
Therapix, Yissum ink nasal drug delivery pact
Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University. According to the deal, Yissum plans to give Therapix an exclusive, global, sub-licensable, royalty-bearing license for its nasal delivery tech to be used with cannabinoids. The technology was developed by […]
Actelion shareholders OK R&D spinout
Actelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ) $30 billion takeover on track to close in the 2nd quarter. The newly formed biopharmaceutical company will be called Idorsia Ltd and led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia […]
Acorda to cut 20% of staff in restructuring effort
Acorda Therapeutics (NSDQ:ACOR) said today that it plans to cut 20% of its workforce as a part of a cost reduction and restructuring effort. The move comes less than 1 week after the company lost patents related to its multiple sclerosis drug, Ampyra. The Ardsley, N.Y.-based company had 597 employees as of February, according to Reuters, […]
More trouble for United’s Remodulin
The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled yesterday that the claims of United Therapeutics‘s (NSDQ:UTHR) patent, which covers Remodulin, are unpatenable due to obviousness. SteadyMed (NSDQ:STDY) challenged the patent in October last year. The patent, No. 8,497,393, relates to the process to purify prostacyclin derivatives, including treprostinil, which is […]
EpiPen purchasers level class action against Mylan over price hikes
Mylan (NSDQ:MYL) was hit with another class action lawsuit over the price of its EpiPen device yesterday. The lawsuit, which was filed in the Washington Western District Court, alleges that Mylan engaged in a scheme with pharmacy benefit managers to dominate the market and overcharge customers. Although the Canonsburg, Penn.-based company has been hit with several lawsuits […]
Researchers mimic bee venom strategy to help drugs get past blood-brain barrier
Researchers from the Institute for Research in Biomedicine in Barcelona, Spain said yesterday that they have shown in preclinical tests that a bee-venom peptide, apamin, can be used to ferry medications across the blood-brain barrier. Although the blood-brain barrier prevents most things from getting in and flooding the brain, certain peptides in animal venoms can travel […]
Sanofi boasts observational hypoglycemia rates for Toujeo insulin injection
Sanofi (NYSE:SNY) touted real-world clinical data for its Toujeo insulin glargine injection from a new observational study. The data from Deliver 2 showed that patients with Type II diabetes who switched to Toujeo from other basal insulins had significantly lower risk of hypoglycemia without compromising blood sugar control. The Deliver 2 study analyzed electronic medical […]